WeVote
Log In

Bill

Bill

SB 2294

AN ACT to create and enact a new section to chapter 19-24.1 of the North Dakota Century Code, relating to qualifying nonresident medical marijuana patients; to amend and reenact subsection 3 of section 19-24.1-01, subsection 4 of section 19-24.1-01, subsection 8 of section 19-24.1-01, subsection 26 of section 19-24.1-01, subsection 47 of section 19-24.1-01, and sections 19-24.1-03, 19-24.1-11, and 19-24.1-37 of the North Dakota Century Code, relating to allowable amounts of usable medical marijuana, medical marijuana recordkeeping, cannabinoid edible products, patient qualifications, and disclosure of information.

69th Legislative Assembly (2025-26) Introduced by Sean Cleary and 5 co-sponsors

North Dakota expands medical marijuana program by increasing possession limits, modifying edible product regulations, and adjusting patient qualifications and disclosure requirements.

Filed with Secretary Of State 04/30
0
WeVote Research Nonpartisan
Bill Summary · SB 2294

Legislative bill overview

SB 2294 expands North Dakota's medical marijuana program by modifying regulations on usable marijuana amounts, recordkeeping requirements, edible products, patient qualifications, and information disclosure rules. The bill specifically addresses how much medical marijuana patients can possess, how the program tracks usage, and what forms marijuana products can take.

Why is this important

Medical marijuana programs require clear regulatory frameworks to balance patient access with public health oversight. These amendments affect thousands of North Dakota medical marijuana cardholders' access to treatment options and determine how the state monitors the program's implementation and safety.

Potential points of contention

  • Increased possession limits: Higher allowable amounts of usable marijuana may concern those worried about abuse potential or unintended recreational use, versus patient advocates who argue current limits restrict legitimate medical treatment
  • Edible product regulations: Expanding cannabinoid edible products creates questions about dosing standards, packaging safety, child-resistant requirements, and distinguishing medical from recreational products
  • Privacy versus oversight: Changes to information disclosure balance patient confidentiality against the state's need to monitor program compliance and detect fraud or diversion

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.